News | Prostate Cancer | September 14, 2015

New Prostate Imaging Agent Improves Detection of Metastatic Cancer Cells

Study results show cancer detected in half of subjects with new agent, compared to none with conventional imaging

ImaginAb, prostate imaging agent, prostate cancer, World Molecular Imaging Conference, molecular imaging, PET

September 14, 2015 — ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

The trial data were presented at the World Molecular Imaging Congress 2015 in Honolulu, Hawaii.

"Accurate detection of extra-prostatic disease in high-risk prostate cancer is critical for providing the best possible care to patients undergoing radical prostatectomy," said Robert Reiter, M.D., co-director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. "However, conventional imaging fails to detect metastatic disease in up to 50 percent of high-risk prostate cancer patients. As our data show, ImaginAb's imaging agent provides a whole-body picture of disease activity, with the potential to change patient management and guide the course of care for best possible outcomes."

Results include the first nine of 20 patients in an ongoing, open-label, Phase 2, single-center trial. Patients received IAB2M intravenously prior to a whole-body positron emission tomography (PET) scan. The agent detected disease in lymph nodes of three of six subjects, later confirmed positive for metastasis at surgery. This is in stark contrast to ProstaScint and conventional imaging, which did not detect metastasis in lymph nodes in any of those subjects.

For more information: www.imaginab.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

News | Computed Tomography (CT) | September 07, 2021
Neuroscientists at the Beckman Institute for Advanced Science and Technology carried out comparative studies to determine safe operating conditions for multiband EEG-fMRI imaging while maintaining acceptable data quality standards

A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Technology including Sepideh Sadaghiani, Maximillian Egan, Ryan Larsen, and Brad Sutton published a study to establish safe use of electroencephalography coupled with newly developed functional MRI sequences. Image courtesy of the Beckman Institute for Advanced Science and Technology.

News | Magnetic Resonance Imaging (MRI) | September 07, 2021
September 7, 2021 — A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Tec
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste